Temporary use of low
dose prednisone monotherapy leads to disease remission and improved clinical severity of the majority of newly diagnosed patients with rheumatoid arthritis (RA),
suggests a study published in the Adv Rheumatol
recommendations endorse the use of glucocorticoids (GCs) for rheumatoid
arthritis (RA) patients’ flares and as a bridge to a DMARD. However, the
recommendation of low dose short-term monotherapy with glucocorticoids (GCs) remains
open to the discretion of the clinician.
A group of researchers
from U.S.A conducted a study to assess whether short-term use of low dose
prednisone monotherapy was effective in inducing remission in newly diagnosed for
rheumatoid arthritis (RA).
The researchers performed a retrospective analysis of patients newly diagnosed with rheumatoid arthritis
(RA) at a Community Health Center in North Dakota was performed based on the
ACR/EULAR RA classification criteria. Demographic and clinical data were
abstracted from patients’ medical charts. Patients treated with (< 10 mg/day) of prednisone up to 6 months were included. Response to prednisone was analyzed according to pre- and post-treatment DAS28-ESR score and EULAR response criteria.
The results of the
study are as follows:
- Data on 201
patients were analyzed.
- The mean
prednisone dose was 8 mg/day and the mean treatment duration was 42.2 days Disease
severity significantly improved from baseline to follow-up for the tender joint
count, swollen joint count, and visual analog pain score.
disease severity significantly improved from baseline to follow-up.
- Per EULAR
response criteria, 69.7% of patients showed good response to treatment and
20.4% showed a moderate response. 54.2% of patients reached remission.
Thus, the researchers concluded
that short-term use of low dose prednisone monotherapy induced disease
remission and improved clinical severity of rheumatoid arthritis in the majority of newly
The efficacy of low
dose short-term prednisone therapy for remission induction in newly diagnosed
rheumatoid arthritis patients by Stacy J et. al published in the Adv Rheumatol.